EMA
approval
· 2024-04-25
EMA Authorised: Pirfenidone axunio (previously Pirfenidone AET) (Pirfenidone) — Axunio Pharma GmbH
Summary
EMA authorised Pirfenidone axunio (Pirfenidone) for idiopathic pulmonary fibrosis under Axunio Pharma GmbH.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Status: Authorised. Therapeutic area: Idiopathic Pulmonary Fibrosis. MAH: Axunio Pharma GmbH. Decision date: 18/04/2024